Euro
USD
British Pound
NULL
Product Description
Brentuximab Antibody, Monoclonal | 21-857 | ProSci
Product Type: Primary Antibodies
Category: Primary Antibodies, Monoclonal Antibodies
Research Area: Drug Analogues
Type: Monoclonal
Host Species: N/A
Reactivity Species: N/A
Homology: N/A
Immunology: Humanized / TNFRSF8 (CD30, D1S166E, Ki-1) [Homo sapiens]
Tested Application: N/A
Application Note: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Predicted Molecular Weight: N/A
Isoform: N/A
Purification: >95%
Clonality: Recombinant Monoclonal
Clone: N/A
Isotype: Human IgG1
Conjugate: Unconjugated
Physical State: N/A
Buffer: PBS buffer pH 7.5
Concentration: N/A
Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at +4°C short term (1-2 weeks) . Store at -20 °C 12 months. Store at -80°C long term.
Additional Names: CD30; Ki-1; D1S166E
Protein Accession: P28908
User Note: For research use only .
Background: Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.
Loading Controls: N/A
Source: CHO cells
Purity: >95%
CAS: N/A
Shipping Condition: N/A
